Literature DB >> 31636094

Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy.

Francesco Negro1.   

Abstract

The hepatitis C virus (HCV) infects 71.1 million persons and causes 400,000 deaths annually worldwide. HCV mostly infects the liver, causing acute and chronic necroinflammatory damage, which may progress toward cirrhosis and hepatocellular carcinoma. In addition, HCV has been associated with several extrahepatic manifestations. The advent of safe and effective direct-acting antivirals (DAAs) has made the dream of eliminating this public health scourge feasible in the medium term. Prospective studies using DAA-based regimens have shown the benefit of HCV clearance in terms of both liver- and non-liver-related mortality.
Copyright © 2020 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31636094      PMCID: PMC7117949          DOI: 10.1101/cshperspect.a036921

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  146 in total

1.  Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma.

Authors:  Marcello Persico; Andrea Aglitti; Rosa Caruso; Amalia De Renzo; Carmine Selleri; Catello Califano; Ludovico Abenavoli; Alessandro Federico; Mario Masarone
Journal:  Hepatology       Date:  2017-11-24       Impact factor: 17.425

2.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

3.  The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Kazuyuki Mizuno; Yasuhiro Sone; Tomoyuki Akita; Junko Tanaka; Philip J Johnson
Journal:  Liver Int       Date:  2018-11-02       Impact factor: 5.828

4.  Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.

Authors:  Salvatore Petta; Luigi Elio Adinolfi; Anna Ludovica Fracanzani; Francesca Rini; Rosalia Caldarella; Vincenza Calvaruso; Calogero Cammà; Marcello Ciaccio; Vito Di Marco; Stefania Grimaudo; Anna Licata; Aldo Marrone; Riccardo Nevola; Rosaria Maria Pipitone; Antonio Pinto; Luca Rinaldi; Daniele Torres; Antonino Tuttolomondo; Luca Valenti; Silvia Fargion; Antonio Craxì
Journal:  J Hepatol       Date:  2018-03-02       Impact factor: 25.083

5.  Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting.

Authors:  Giovanni Perricone; Christophe Duvoux; Marina Berenguer; Paolo A Cortesi; Carmen Vinaixa; Rita Facchetti; Chiara Mazzarelli; Susanne-Rasoul Rockenschaub; Silvia Martini; Cristina Morelli; Sara Monico; Riccardo Volpes; Georges-Philippe Pageaux; Stefano Fagiuoli; Luca S Belli
Journal:  Liver Int       Date:  2018-05-25       Impact factor: 5.828

Review 6.  Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis.

Authors:  Hla-Hla Thein; Qilong Yi; Gregory J Dore; Murray D Krahn
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

7.  Depression and neuroticism in patients with chronic hepatitis C: correlation with peripheral blood mononuclear cells activation.

Authors:  Tomasz Pawlowski; Marek Radkowski; Krzysztof Małyszczak; Małgorzata Inglot; Małgorzata Zalewska; Joanna Jablonska; Tomasz Laskus
Journal:  J Clin Virol       Date:  2014-03-15       Impact factor: 3.168

8.  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Authors:  David Roth; David R Nelson; Annette Bruchfeld; AnnMarie Liapakis; Marcelo Silva; Howard Monsour; Paul Martin; Stanislas Pol; Maria-Carlota Londoño; Tarek Hassanein; Philippe J Zamor; Eli Zuckerman; Shuyan Wan; Beth Jackson; Bach-Yen Nguyen; Michael Robertson; Eliav Barr; Janice Wahl; Wayne Greaves
Journal:  Lancet       Date:  2015-10-05       Impact factor: 202.731

9.  Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.

Authors:  Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal; Graham R Foster; William L Irving
Journal:  J Hepatol       Date:  2016-07-05       Impact factor: 30.083

10.  Factors Associated with Improved Glycemic Control by Direct-Acting Antiviral Agent Treatment in Egyptian Type 2 Diabetes Mellitus Patients with Chronic Hepatitis C Genotype 4.

Authors:  Alaaeldin Abdelsalam Dawood; Mohamed Zakarya Nooh; Ayman Abdelhaleem Elgamal
Journal:  Diabetes Metab J       Date:  2017-08       Impact factor: 5.376

View more
  4 in total

Review 1.  Risk of hepatocellular carcinoma after hepatitis C virus cure.

Authors:  Maria Alejandra Luna-Cuadros; Hao-Wei Chen; Hira Hanif; Mukarram Jamat Ali; Muzammil Muhammad Khan; Daryl Tan-Yeung Lau
Journal:  World J Gastroenterol       Date:  2022-01-07       Impact factor: 5.742

Review 2.  The Role of the Microbiota Gut-Liver Axis during HCV Chronic Infection: A Schematic Overview.

Authors:  Nadia Marascio; Carmen De Caro; Angela Quirino; Maria Mazzitelli; Emilio Russo; Carlo Torti; Giovanni Matera
Journal:  J Clin Med       Date:  2022-10-08       Impact factor: 4.964

3.  Immune Activation Induces Telomeric DNA Damage and Promotes Short-Lived Effector T Cell Differentiation in Chronic HCV Infection.

Authors:  Lam Nhat Nguyen; Lam Ngoc Thao Nguyen; Juan Zhao; Madison Schank; Xindi Dang; Dechao Cao; Sushant Khanal; Bal Krishna Chand Thakuri; Jinyu Zhang; Zeyuan Lu; Xiao Y Wu; Mohamed El Gazzar; Shunbin Ning; Ling Wang; Jonathan P Moorman; Zhi Q Yao
Journal:  Hepatology       Date:  2021-08-25       Impact factor: 17.425

Review 4.  Adaptive Immune Response against Hepatitis C Virus.

Authors:  Janine Kemming; Robert Thimme; Christoph Neumann-Haefelin
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.